Early Dual IV Antibiotic Therapy - MSSA — Competitive Intelligence Brief

Early Dual IV Antibiotic Therapy - MSSA (Early Dual IV Antibiotic Therapy - MSSA) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antibiotic combination therapy. Area: Infectious Disease.

marketed Antibiotic combination therapy Infectious Disease Small molecule

Target snapshot

Early Dual IV Antibiotic Therapy - MSSA (Early Dual IV Antibiotic Therapy - MSSA) — West Virginia University. Early dual IV antibiotic therapy uses two intravenous antibiotics simultaneously to treat methicillin-sensitive Staphylococcus aureus (MSSA) infections with broader coverage and reduced resistance risk.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Early Dual IV Antibiotic Therapy - MSSA TARGET	Early Dual IV Antibiotic Therapy - MSSA	West Virginia University	marketed	Antibiotic combination therapy
Omeprazole, Amoxicillin, Metronidazole and Clarithromycin	Omeprazole, Amoxicillin, Metronidazole and Clarithromycin	Al-Azhar University	marketed	Proton pump inhibitor + antibiotic combination therapy	H+ ATPase (omeprazole); bacterial ribosome and cell wall (amoxicillin, clarithromycin); bacterial DNA (metronidazole)
Optimized bismuth quadruple therapy	Optimized bismuth quadruple therapy	Pontificia Universidad Catolica de Chile	marketed	Antibiotic combination therapy / Bismuth-based H. pylori eradication regimen
clarithromycin-based triple therapy	clarithromycin-based triple therapy	National Taiwan University Hospital	marketed	Macrolide antibiotic combination therapy	Bacterial 50S ribosome (clarithromycin component)
metronidazole based quadriple therapy	metronidazole based quadriple therapy	mohamed bouchoucha	marketed	Antibiotic combination therapy	Helicobacter pylori DNA and bacterial cell integrity
Early Dual IV Antibiotic Therapy - MRSA	Early Dual IV Antibiotic Therapy - MRSA	West Virginia University	marketed	Antibiotic combination therapy
PPI-amoxicillin-clarithromycin	PPI-amoxicillin-clarithromycin	National Taiwan University Hospital	marketed	Antibiotic combination therapy with acid suppression	Helicobacter pylori (bacterial pathogen); PPI targets H+/K+-ATPase; amoxicillin targets bacterial cell wall; clarithromycin targets bacterial ribosome

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antibiotic combination therapy class)

1. West Virginia University · 2 drugs in this class
2. Mackay Memorial Hospital · 1 drug in this class
3. Takeda · 1 drug in this class
4. University of Valencia · 1 drug in this class
5. mohamed bouchoucha · 1 drug in this class